FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 332:1491-1498 June 1, 1995 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article PubMed Citation

Epidemiologic, clinical, genetic, experimental, and pathological studies have clearly established the primary role of lipoproteins in atherogenesis.^1,2 Lowering plasma cholesterol concentrations reduces the availability of atherogenic lipoproteins and also, presumably, the accumulation of cholesterol in the intima of arteries. Measures to lower plasma cholesterol have become fundamental to the practice of preventive cardiology, and their use in both patients who already have coronary disease and healthy people has materially contributed to the 50 percent reduction in mortality from coronary heart disease in the United States in the past two decades.^3,4

Lowering the plasma cholesterol concentration by a variety of means, . . . [Full Text of this Article]

Atherogenic and Antiatherogenic Lipoproteins

Low-Density Lipoprotein Cholesterol

The Atherogenic Lipoprotein Phenotype

Plasma Lipoprotein(A)

Plasma HDL Cholesterol

Measurement of Lipoproteins in Risk Assessment

Plasma LDL Cholesterol

Plasma Non-HDL Cholesterol

Plasma Triglycerides and HDL Cholesterol

Prevention and Treatment of Atherogenic Hyperlipidemia

Primary Prevention

            Screening

            Treatment

Secondary Prevention

            Potential for Reducing Morbidity and Mortality

            Treatment

Coronary-Artery Bypass Surgery

Percutaneous Coronary Angioplasty

Treatment of Women

Treatment of Patients with Hypertension or Diabetes Mellitus

Treatment of the Elderly

Conclusions

Source Information

From the Cardiovascular Research Institute and the Department of Medicine, University of California, San Francisco, CA 94143-0130, where reprint requests should be addressed to Dr. Havel.

References

This article has been cited by other articles:

• McMahan, C. A., Gidding, S. S., Malcom, G. T., Tracy, R. E., Strong, J. P., McGill, H. C. Jr, for the Pathobiological Determinants of Atheroscle, (2006). Pathobiological Determinants of Atherosclerosis in Youth Risk Scores Are Associated With Early and Advanced Atherosclerosis. Pediatrics 118: 1447-1455 [Abstract] [Full Text]  
• Srinivasan, S. R., Frontini, M. G., Xu, J., Berenson, G. S. (2006). Utility of Childhood Non-High-Density Lipoprotein Cholesterol Levels in Predicting Adult Dyslipidemia and Other Cardiovascular Risks: The Bogalusa Heart Study. Pediatrics 118: 201-206 [Abstract] [Full Text]  
• McMahan, C. A., Gidding, S. S., Fayad, Z. A., Zieske, A. W., Malcom, G. T., Tracy, R. E., Strong, J. P., McGill, H. C. Jr, for the Pathobiological Determinants of Atheroscle, (2005). Risk Scores Predict Atherosclerotic Lesions in Young People. Arch Intern Med 165: 883-890 [Abstract] [Full Text]  
• Enkhmaa, B., Shiwaku, K., Katsube, T., Kitajima, K., Anuurad, E., Yamasaki, M., Yamane, Y. (2005). Mulberry (Morus alba L.) Leaves and Their Major Flavonol Quercetin 3-(6-Malonylglucoside) Attenuate Atherosclerotic Lesion Development in LDL Receptor-Deficient Mice. J. Nutr. 135: 729-734 [Abstract] [Full Text]  
• Zhang, J., Muldoon, M. F, McKeown, R. E (2004). Serum cholesterol concentrations are associated with visuomotor speed in men: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Am. J. Clin. Nutr. 80: 291-298 [Abstract] [Full Text]  
• Lu, W., Resnick, H. E., Jablonski, K. A., Jones, K. L., Jain, A. K., Howard, Wm. J., Robbins, D. C., Howard, B. V. (2003). Non-HDL Cholesterol as a Predictor of Cardiovascular Disease in Type 2 Diabetes: The Strong Heart Study. Diabetes Care 26: 16-23 [Abstract] [Full Text]  
• Hsia, S. H. (2003). Non-HDL Cholesterol: Into the Spotlight. Diabetes Care 26: 240-242 [Full Text]  
• Srinivasan, S. R., Myers, L., Berenson, G. S. (2002). Distribution and Correlates of Non-High-Density Lipoprotein Cholesterol in Children: The Bogalusa Heart Study. Pediatrics 110: e29-29 [Abstract] [Full Text]  
• Levinson, S. S. (2002). High Density- and Beta-Lipoprotein Screening for Risk of Coronary Artery Disease in the Context of New Findings on Reverse Cholesterol Transport. Annals of Clinical & Laboratory Science 32: 123-136 [Abstract] [Full Text]  
• Cui, Y., Blumenthal, R. S., Flaws, J. A., Whiteman, M. K., Langenberg, P., Bachorik, P. S., Bush, T. L. (2001). Non-High-Density Lipoprotein Cholesterol Level as a Predictor of Cardiovascular Disease Mortality. Arch Intern Med 161: 1413-1419 [Abstract] [Full Text]  
• Yasunari, K., Maeda, K., Minami, M., Yoshikawa, J. (2001). HMG-CoA Reductase Inhibitors Prevent Migration of Human Coronary Smooth Muscle Cells Through Suppression of Increase in Oxidative Stress. Arterioscler. Thromb. Vasc. Bio. 21: 937-942 [Abstract] [Full Text]  
• McGill, H. C. Jr, McMahan, C. A., Zieske, A. W., Malcom, G. T., Tracy, R. E., Strong, J. P. (2001). Effects of Nonlipid Risk Factors on Atherosclerosis in Youth With a Favorable Lipoprotein Profile. Circulation 103: 1546-1550 [Abstract] [Full Text]  
• Avins, A. L., Neuhaus, J. M. (2000). Do Triglycerides Provide Meaningful Information About Heart Disease Risk?. Arch Intern Med 160: 1937-1944 [Abstract] [Full Text]  
• Havel, R. J., Frost, P. H. (2000). The Role of Non-High-Density Lipoprotein-Cholesterol in Evaluation and Treatment of Lipid Disorders. J. Clin. Endocrinol. Metab. 85: 2105-2108 [Full Text]  
• Sundquist, J., Winkleby, M. (2000). Country of birth, acculturation status and abdominal obesity in a national sample of Mexican-American women and men. Int J Epidemiol 29: 470-477 [Abstract] [Full Text]  
• Zema, M. J. (2000). Gemfibrozil, nicotinic acid and combination therapy in patients with isolated hypoalphalipoproteinemia: a randomized, open-label, crossover study. J Am Coll Cardiol 35: 640-646 [Abstract] [Full Text]  
• Anderson, J. W, Allgood, L. D, Lawrence, A., Altringer, L. A, Jerdack, G. R, Hengehold, D. A, Morel, J. G (2000). Cholesterol-lowering effects of psyllium intake adjunctive to diet therapy in men and women with hypercholesterolemia: meta-analysis of 8 controlled trials1. Am. J. Clin. Nutr. 71: 472-479 [Abstract] [Full Text]  
• Knopp, R. H. (1999). Drug Treatment of Lipid Disorders. NEJM 341: 498-511 [Full Text]  
• Winkleby, M. A., Robinson, T. N., Sundquist, J., Kraemer, H. C. (1999). Ethnic Variation in Cardiovascular Disease Risk Factors Among Children and Young Adults: Findings From the Third National Health and Nutrition Examination Survey, 1988-1994. JAMA 281: 1006-1013 [Abstract] [Full Text]  
• Winkleby, M. A., Kraemer, H. C., Ahn, D. K., Varady, A. N. (1998). Ethnic and Socioeconomic Differences in Cardiovascular Disease Risk Factors: Findings for Women From the Third National Health and Nutrition Examination Survey, 1988-1994. JAMA 280: 356-362 [Abstract] [Full Text]  
• Borgia, M. C., Medici, F. (1998). Perspectives in the Treatment of Dyslipidemias in the Prevention of Coronary Heart Disease. ANGIOLOGY 49: 339-348 [Abstract]  
• Banga, J. D. (1998). Invited Review. VASC ENDOVASCULAR SURG 32: 245-247  
• Havel, R. J. (1997). Benefits of Fibrate Drugs in Coronary Heart Disease Patients With Normal Cholesterol Levels. Circulation 96: 2113-2114 [Full Text]  
• Jeppesen, J., Hein, H. O., Suadicani, P., Gyntelberg, F. (1997). Relation of High TG–Low HDL Cholesterol and LDL Cholesterol to the Incidence of Ischemic Heart Disease: An 8-Year Follow-up in the Copenhagen Male Study. Arterioscler. Thromb. Vasc. Bio. 17: 1114-1120 [Abstract] [Full Text]  
• Hodis, H. N., Mack, W. J., Dunn, M., Liu, C.-r., Liu, C.-h., Selzer, R. H., Krauss, R. M. (1997). Intermediate-Density Lipoproteins and Progression of Carotid Arterial Wall Intima-Media Thickness. Circulation 95: 2022-2026 [Abstract] [Full Text]  
• Grundy, S. M. (1997). Small LDL, Atherogenic Dyslipidemia, and the Metabolic Syndrome. Circulation 95: 1-4 [Full Text]  
• Frost, P. H., Davis, B. R., Burlando, A. J., Curb, J. D., Guthrie, G. P., Isaacsohn, J. L., Wassertheil-Smoller, S., Wilson, A. C., Stamler, J. (1996). Serum Lipids and Incidence of Coronary Heart Disease: Findings From the Systolic Hypertension in the Elderly Program (SHEP). Circulation 94: 2381-2388 [Abstract] [Full Text]  
• Gardner, C. D., Fortmann, S. P., Krauss, R. M. (1996). Association of Small Low-Density Lipoprotein Particles With the Incidence of Coronary Artery Disease in Men and Women. JAMA 276: 875-881 [Abstract]  
• Mack, W. J., Krauss, R. M., Hodis, H. N. (1996). Lipoprotein Subclasses in the Monitored Atherosclerosis Regression Study (MARS) : Treatment Effects and Relation to Coronary Angiographic Progression. Arterioscler. Thromb. Vasc. Bio. 16: 697-704 [Abstract] [Full Text]  
• Pedersen, T. R. (1995). Lowering Cholesterol with Drugs and Diet. NEJM 333: 1350-1351 [Full Text]